METX — ME Therapeutics Holdings Income Statement
0.000.00%
Last trade - 00:00- CA$266.30m
- CA$264.40m
- 45
- 20
- 77
- 45
Annual income statement for ME Therapeutics Holdings, fiscal year end - August 31st, CAD millions except per share, conversion factor applied.
2020 August 31st | 2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.105 | 0.071 | 0.163 | 6.55 | 1.37 |
| Operating Profit | -0.105 | -0.071 | -0.163 | -6.55 | -1.37 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.052 | -0.071 | -0.146 | -6.52 | -1.29 |
| Net Income After Taxes | -0.052 | -0.071 | -0.146 | -6.52 | -1.29 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.052 | -0.071 | -0.146 | -6.52 | -1.29 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.052 | -0.071 | -0.146 | -6.52 | -1.29 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.002 | -0.003 | -0.006 | -0.04 | -0.053 |
| Dividends per Share |